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Dr Moralesa
doi:10.1016/j.jtcvs.2006.03.061bjective: The Contegra conduit was developed for right ventricular outflow tract
econstruction. This report evaluates the Contegra conduit, with focus on certain
ubpopulations in which conduits are known to perform poorly (ie, patients with
revious homograft conduits and infants).
ethods: A retrospective review of 76 patients who had 77 Contegra conduits
laced for right ventricular outflow tract reconstruction (January 2001 through
ugust 2005) was completed. Characteristics include the following: median age of
.6 years (range, 17 days-15.1 years), weight of 9.8 kg (range, 2.5-64.0 kg), and
onduit diameter of 16 mm (range, 12-22 mm). Operations performed include right
entricular outflow tract reconstruction for pulmonary atresia–stenosis (n  33),
onduit exchange (n  28), truncus repair (n  7), primary conduit placement (n 
), and the Ross procedure (n  3). Seventy-nine percent were reoperations.
esults: There was no hospital mortality. Mean follow-up was 20  14 months.
ne-, 2-, and 3- year freedom from severe conduit regurgitation was 97%, 86%, and
1%, respectively, and freedom from severe conduit stenosis was 100%. Freedom
rom reoperation for conduit failure at 1 and 3 years is 98.3% and 93.1%, respec-
ively. All conduit failures (n 3) were for asymptomatic conduit pseudoaneurysms
n the setting of multiple-level pulmonary branch stenoses. Survival at 3 years is
6%. Infants (n  26) had a freedom from Contegra conduit failure at 3 years of
00%. Patients with previous homograft conduits (n  26) had a freedom from
ontegra conduit failure at 3 years of 100%.
onclusion: At midterm follow-up, the Contegra conduit remains a reliable, acces-
ible, and easily implantable conduit for right ventricular outflow tract reconstruc-
ion. It appears to be the most promising conduit option for patients with previous
omograft conduits and for infants.
econstruction of the congenitally abnormal right ventricle (RV)–to–
pulmonary artery (PA) tract presents a significant challenge for the con-
genital heart surgeon. The long-term life expectancy of patients after ven-
ricular outflow tract operations continues to be less than that of the general
opulation.1 In the absence of a perfect conduit, the search for an optimal e
V-PA conduit continues. Since its introduction in 1999, the Contegra bovine
ugular vein conduit (Medtronic, Inc, Minneapolis, Minn) has received much
nterest because of several inherent advantages. Unlike cryopreserved homograft
alved conduits, it is readily available in many sizes (12-22 mm) and is compara-
ively less expensive. Compared with other conduits, it is especially pliable, with
xcellent suturing and tailoring characteristics.2 The conduit is fixed with 0.6
luteraldehyde under zero pressure conditions, and with no additional anticalcifi-
ation treatment, it has demonstrated an excellent durability, low calcification rate,
nd low rate of stenosis in animal trials.3-6 Most importantly, several clinical reports
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Dave shown excellent early and midterm hemodynamic and
linical results that compare favorably with the results of
ryopreserved homograft valved conduits, the gold standard
f RV-PA conduits.7-11 Despite being the gold standar
omograft conduits have consistently performed poorly in
ertain patient cohorts, specifically patients with previous
omograft conduits and infants.12-15 The aims of this stud
ere to evaluate the Contegra conduit’s function and dura-
ility and to analyze its performance in those subpopula-
ions in which homograft conduits have unsatisfactory
esults.
ethods
atient Population
etween January 2001 and August 2005, 76 patients between 17
ays and 15.1 years old underwent 77 RV-PA reconstructions with
he Contegra valved bovine jugular vein conduit (Figure 1
exas Children’s Hospital (TCH). Their medical records were
etrospectively reviewed with the approval of the Baylor College
f Medicine Institutional Review Board. Mean weight was 13.5 
2.1 kg. Thirty-four percent (n  26) of the entire cohort were
nfants. All available sizes of the Contegra conduit (12-22 mm)
ere implanted, with the median size being 16 mm. Indications for
urgical intervention included pulmonary atresia (n 31), replace-
ent of a previous conduit (n  28; 26 homografts, 1 Contegra
onduit, and 1 polytetrafluoroethylene* conduit), truncus arterio-
us (n  8), tetralogy of Fallot (n  6), aortic valve disease (the
oss procedure; n  3), and D-transposition of the great arterie1
ince receiving its human device exemption, the Contegra conduit
s not a conduit option in the United States for the Ross procedure.
ixty-one (79%) of the 77 conduit placements were in patients
ndergoing a reoperation. All patients underwent preoperative,
ransthoracic, 2-dimensional echo-Doppler examination and intra-
perative transesophageal echocardiography. Of the 46 children
ho had preoperative catheterizations, 6 (13%) had PA or conduit
ngioplasty or stents.
urgical Technique
ll patients underwent median sternotomy, direct aortobicaval
annulation, and cardiopulmonary bypass (CPB). Other concomi-
ant procedures included ventricular septal defect closure (n 41),
runcus repair (n  7), Blalock-Taussig shunt takedown (n  14),
he Ross procedure (n 3), and truncal valve replacement (n 1).
Abbreviations and Acronyms
CI  confidence interval
CPB  cardiopulmonary bypass
PA  pulmonary artery
PAR  pulmonary artery resistance
RV  right ventricle
RVOT right ventricular outflow tract
TCH  Texas Children’s Hospitalt
Gore-Tex conduit, registered trademark of W. L. Gore & Associates, Inc,
ewark, Del.
66 The Journal of Thoracic and Cardiovascular Surgery ● Septeean CPB time was 197.5 74.8 minutes. Mean crossclamp time
as 103.6  79.3 minutes. All conduits exchanged without a
oncomitant procedure were done on CPB with a beating heart.
he implantation technique was guided by the principles of (1)
rimming the distal graft to make the distance between the valve
nd the distal anastomosis as short as possible, (2) ensuring the
onduit was thoroughly washed to avoid bleeding of the gluteral-
ehyde, (3) creating a generous pulmonary arteriotomy that widely
plays open the PAs, and (4) oversizing of the conduit. Conduit
versizing is especially practiced in the infant population, where
he largest conduit that can fit comfortably in the mediastinum is
sed. However, this oversizing is tempered by the consideration of
ternal compression. When the anatomy is favorable, the conduit is
laced as lateral as possible to the left. A course rightward of the
orta is avoided when possible. Each of the anastomoses is created
ith running Prolene sutures (Ethicon, Inc, Somerville, NJ). No
atient left the operating room with more than mild conduit insuf-
ciency or stenosis.
ostoperative Care and Follow-up
ll patients underwent postoperative transesophageal echocardi-
graphy while still in the operating room. Hospital morbidity end
oints observed were postoperative hemorrhage (requiring reop-
ration), sepsis (bacteremia with hemodynamic compromise), and
eurologic event. After discharge, 40 (53%) patients with the
ontegra conduit had routine echocardiography follow-up as part
f a multi-institutional US Food and Drug Administration study at
month, 3 months, 6 months, 1 year, and yearly thereafter. All
ther patients were followed and underwent echocardiography at
he discretion of the referring cardiologist. All patients were started
n aspirin for anticoagulation. No patient was started on another
nticoagulant because of the conduit. There was a mean follow-up
nterval of 19.7  13.6 months. Twenty-four (32%) of the 76
atients have been followed for 2 years or more. Conduit failure is
efined as exchanging the conduit because of a problem with the
onduit. Stenosis was defined as mild when the peak velocity
cross the conduit was less than 2.5 m/s, moderate when it was 2.5
o 4.5 m/s, and severe when it was 4.5 m/s or greater. The peak
elocity was measured throughout the length of the conduit, and
Figure 1. Age distribution of the study cohort.he maximum value was used.
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Dtatistical Analysis
he follow-up data for survival, reoperation, reintervention, and
onduit function were analyzed by using standard Kaplan-Meier
nalysis. Nonparametric, binomial, and descriptive statistics were
omputed when appropriate. The Fisher exact test was used to
nalyze binary variables.
esults
ospital Course
here were no hospital deaths. Length of intubation was 2.9
4.1 days. Intensive care unit length of stay was 5.2  5.2
ays. One patient was chronically intubated preoperatively
nd remained so at home after discharge. Mean hospital
ength of stay was 12.5  14.3 days. There were no neu-
ologic events, episodes of sepsis, or postoperative hemor-
hages requiring reoperation.
ortality and Reintervention
ne patient died of congestive heart failure 34 days after the
peration. This was a 17-day-old infant with truncus arte-
iosus who was taken to the operating room in cardiogenic
hock caused by a myocardial infarction in evolution and
evere truncal insufficiency. He underwent truncus arterio-
us repair with a 12-mm conduit and was discharged home
7 days after the operation. He returned to the clinic 5 days
ater poorly perfused. He was difficult to resuscitate and
ventually arrested and died. His autopsy stated that his
udden decompensation could be related to thrombi in the
inuses obstructing the conduit’s valve orifice. Clinically, it
ppeared that poor cardiac output superimposed on signif-
cant preexisting endocardial ischemia and damage accen-
uated myocardial dysfunction and led to death.
The second death occurred in a patient who presented at
years of age with tetralogy of Fallot and renal failure that
equired dialysis preoperatively. Her hospital course at the
ime of repair was uneventful; however, she was severely
ehydrated and septic at presentation 20 months postoper-
tively. She went into multisystem organ failure and died 3
eeks after admission on postoperative day 517.
Survival at 1 and 3 years is 98.6% and 96.4%, respectively.
Seven patients with the Contegra conduit had a reopera-
ion. Two patients had reoperations unrelated to the Con-
egra conduit, which was left in place. Two conduits that
ere functionally sound were exchanged during reopera-
ions for non–conduit-related issues and to facilitate access
o other structures. Three exchanges were required for con-
uit failure at a mean interval of 337  144 days. All
ailures were caused by pseudoaneurysms at the proximal
nastomosis. Freedom from reoperation for conduit failure
as 98.3% (95% confidence interval [CI], 0.92-0.99) at 1
ear and 93.1% (95% CI, 0.85-0.96) at 3 years (Figu
f the patients with pseudoaneurysms, all were asymptom-
tic. All 3 patients had the diagnosis of pulmonary atresia
nd ventricular septal defect with major aortopulmonary i
The Journal of Thoracic).
ollateral arteries. One patient had a dehiscence of his ven-
ricular septal defect patch after a febrile illness and had a chest
adiograph that demonstrated a mass in the left superior me-
iastinum. A cardiac catheterization demonstrated a large
seudoaneurysm of the right ventricular outflow tract (RVOT).
he second patient underwent a routine follow-up echocardio-
ram, which revealed a pseudoaneurysm in the RVOT. The
hird patient had difficult distal branch PA reconstruction at
he primary operation and was scheduled for cardiac cath-
terization 6 months later, which revealed a large pseudo-
neurysm at the proximal anastomosis of the conduit (
re 3). All patients undergoing reoperation were dischar
nd are still alive.
Seven patients had balloon angioplasty of or stent place-
ent in their PAs distal to the conduit. Four patients un-
erwent interventional catheterization on the conduit at a
ean interval of 17.5  9.9 months. One patient had
alloon angioplasty of bilateral PAs and conduit stent place-
ent, and 3 patients had balloon angioplasty of their distal
onduits. Freedom from catheter intervention on the conduit
s 98.5% (95% CI, 0.91-0.99) at 1 year and 92.9% (95% CI,
.85-0.96) at 2 years.
In addition to the patient who died, one other patient had
small thrombus in the conduit valve sinuses discovered
uring routine echocardiographic follow-up. This patient
as been asymptomatic and receives aspirin therapy only.
he thrombus has not changed in 3 years.
onduit Function
he overall freedom from severe conduit stenosis is 100%
t 3 years, and freedom from moderate stenosis at 1, 2, and
 years is 100%, 92%, and 82%, respectively (Figure 4A).
he freedom from severe regurgitation at 1, 2, and 3 years
igure 2. Freedom from reoperation for Contegra conduit failure.
ertical lines represent 95% confidence intervals.s 97%, 86%, and 81%, respectively, and that from moder-
and Cardiovascular Surgery ● Volume 132, Number 3 667
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Dte regurgitation is 91%, 80%, and 64%, respectively (
re 4, B). The mean time interval between the day o
peration and the last echocardiographic follow-up was 1.5
1.2 years. Of the 6 patients who had a preoperative PA
esistance (PAR) of greater than 2.5 Woods units or mean
A pressures of greater than 18 mm Hg, 67% (n  4) had
oderate or severe pulmonary insufficiency compared with
5% (n  17) for the rest of the cohort (P  .07).
ubpopulation Results
n the infant population (n  26; mean age, 6.7  3.8
onths; mean weight, 6.1  2.2 kg; mean follow-up,
8.3  11.3 months) freedom from failure at 3 years is
00%. One infant required catheter intervention and balloon
onduit plasty at 31⁄2 years. In patients with previous RV-PA
omograft conduits (n  26; mean age, 5.4  3.8 years;
ean follow-up, 19.5 16.3 months), freedom from failure
t 3 years is 100%. None of these patients have required
atheter intervention on the conduit.
iscussion
ince receiving human device exemption approval in No-
ember 2003, the Contegra bovine jugular vein conduit has
een increasingly used for RVOT reconstruction. One rea-
on that the Contegra conduit has enjoyed such a wide
cceptance is the lack of a clearly superior RV-PA conduit.
he Shelhigh porcine-valved conduit (Shelhigh, Inc, Union,
J) and porcine xenografts have proved disappointing.16-18
acron xenograft valve conduits, like the Hancock conduit
Medtronic, Inc), have had good short and midterm results
ut are difficult to implant, require preclotting, and have a
endency toward stenosis and calcification, especially in
mall-diameter conduits.19 Therefore their use in infants h
een avoided. In the TCH experience the Perimount bovine
ericardial tissue prosthesis (Edwards Lifesciences, Irvine,
alif) appears to be a promising option when seeking to s
68 The Journal of Thoracic and Cardiovascular Surgery ● Septerovide pulmonary valve competence, such as in patients
ith previous transventricular repair of tetralogy of Fallot.
owever, it cannot be used to reconstruct the RVOT and it
annot be used in smaller children.
Since the homograft became the conduit of choice for
VOT reconstruction in the mid-1980s, the superiority of
omograft conduit performance to xenograft composite
onduits in terms of durability, function, and malleability
as been reported numerous times.9,13,16 However, a re-
ent report by Brown and colleagues12 conveyed an un-
atisfying performance for homograft conduits at a mid-
erm follow-up of 5 years. Homograft dysfunction and
ailure were 60% and 40%, respectively. The TCH expe-
ience with the Contegra conduit demonstrates a 3-year
onduit failure rate of 7%. Boethig and associates11 have
eported a freedom from explantation of 100% at 4 years
or the Contegra conduit, whereas homografts in the same
tudy had an explantation rate of 20% over the same time
eriod. Therefore the Contegra conduit appears comparable
ith, if not better than, the presently available RV-PA conduits
freedom from conduit replacement for pulmonary homografts
f 80% at 3 years; Shelhigh, 30% at 18 months; porcine
enografts, 30% at 2 years; and porcine-valved conduits-Han-
ock, 90% at 2 years).11,16-19
More importantly, the Contegra conduit appears to have
uperior results in subpopulations in which all other RV-PA
onduits, especially the homograft, have had particularly
oor results (ie, patients with prior homografts and infants).
rown and colleagues12 reported an incidence for h-
ograft conduit dysfunction and failure of 79% and 58%,
espectively, for their infant cohort. This high rate of failure
as also been seen in several other studies that described the
ncreased risk of homograft degeneration when used for
VOT reconstruction in infants.13-15 Limited availability o
Figure 3. A, Angiogram of pseu-
doaneurysm (anteroposterior
view). B, Angiogram of pseudo-
aneurysm (lateral view).mall-sized homografts for infants often results in the com-
mber 2006
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Dromise of conduit selection, which factors into the rate of
onduit failure.20 This compromise manifests itself in t
se of downsized larger conduits or use of slightly flawed
onduits because of limited supply. Although many believe
hat a stronger predictor of conduit failure in infants is
atient size and not conduit type,20-23 the TCH experienc
ith the Contegra conduit demonstrates that conduit type is
mportant. The Contegra conduit’s constant availability in
any sizes allows the surgeon to consistently apply an
versized and reliable conduit. The 26 infants who had the
ontegra conduit placed in this series had a 100% freedom
rom conduit failure at 3 years.
Another advantage of the Contegra conduit is its prom-
sing performance in patients who have had previous
V-PA reconstructions with cryopreserved homografts. o
The Journal of Thoracicany centers have avoided using a second homograft con-
uit in these patients because of the higher rate of failure of
he second homograft conduit compared with that of the
riginal homograft.24 Using multivariate analysis, Stark an
oworkers25 found that a previous homograft was the m
ignificant risk factor for second homograft failure. Many
elieve this to be a result of a heightened immune state
aused by viable endothelial cells in the first homograft.
his immune response to homografts has been clearly doc-
mented by several groups who have shown a significant
ncrease in panel reactive antibody levels after homograft
nsertion.23,26,27 Many hypothesize that this immune st
ccentuates the failure of the second homograft by means of
n immune-mediated narrowing of the conduit. The devel-
Figure 4. A, Freedom from moderate or severe
conduit stenosis. B, Freedom from moderate or
severe conduit regurgitation. Vertical lines rep-
resent 95% confidence intervals.pment of the SynerGraft pulmonary allograft (CryoLife,
and Cardiovascular Surgery ● Volume 132, Number 3 669
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Dnc, Kennesaw, Ga) is an attempt to address this immune
esponse issue.23,26,27 In patients with previous homograf
he TCH preference is to use the Contegra conduit. The
reedom from conduit exchange at 3 years is 100% in this
opulation.
As with all RV-PA conduits, inherent disadvantages of
he Contegra conduit exist. Patients with high PA pressures
nd PARs have a higher rate of conduit insufficiency. This
nding is not surprising because the Contegra conduit con-
ains a venous valve not created for high pressures. This
rend toward insufficiency probably did not reach statistical
ignificance in this study because of the limited number of
atients with high pulmonary pressures who received Con-
egra conduits. These limited numbers are a result of a
anagement decision during this current series to cau-
iously apply the Contegra conduit in patients with high PA
ressures. This policy is based on the earlier experiences in
he series. In addition to this consideration, the length of the
ontegra conduit’s valve can be prohibitive in certain low-
irth-weight children (2.5 kg) when the distance between
he RV opening and the PAs is short. Also, larger adults
sually receive a Perimount valve or a Hancock conduit at
CH because 22 mm is the largest Contegra conduit size. In
lmost all other cases, the Contegra conduit’s application is
referred over that of other conduits, especially in neonates.
Pseudoaneurysm formation in patients with compro-
ised PA vasculature or high PARs are also a concern with
he Contegra conduit. We theorize that the treatment of the
onduit that prevents calcification also minimizes pericon-
uit adhesions and tissue ingrowth, which contributes to the
tructural integrity of most conduit anastomoses. The lack
f this healing process in patients with increased PA pres-
ures might contribute to pseudoaneurysm formation. Al-
hough surgical technique must be considered as a cause, the
evelopment of psuedoaneurysms was not limited to one
urgeon, and pseudoaneurysm formation has not been a
omplication at TCH with the use of other RV-PA conduits.
oreover, there are other reports of pseudoaneurysm for-
ation in the literature,28-30 all in similar patients. Therefo
he application of the Contegra conduit in patients with a
ompromised pulmonary vasculature (multilevel stenoses)
r a high PAR is approached cautiously.
Thrombosis is another concern with the Contegra con-
uit. Several centers have recently reported cases of throm-
us formation in the Contegra conduit in early and midterm
ollow-up.28,29,31,32 Some groups suggest the use of anti-
gulation during the first postoperative weeks in response to
he potential for early valve failure caused by a local throm-
otic process.2,29 The TCH practice is to use aspirin o
ecause the presence of a thrombus has not been a signifi-
ant factor in a patient’s clinical course or the conduit’s
unction in this series.
70 The Journal of Thoracic and Cardiovascular Surgery ● SepteThis report reconfirms the Contegra conduit’s favorable
utcome in function and durability at short-term and mid-
erm follow-up. Vigilance is still required regarding throm-
us formation and asymptomatic pseudoaneurysms. More-
ver, the Contegra conduit’s durability and function in a
igh-pressure circulation warrants further study. Overall,
he TCH experience reinforces the growing enthusiasm
bout the Contegra conduit as a reliable, accessible, and
asily implantable conduit for RVOT reconstruction. Most
mportantly, the Contegra conduit presently appears to be
he most promising RV-PA conduit option for patients with
revious homograft conduits and for infants.
We thank Dr Dan Graves for his contribution to the statistical
nalyses of the data presented in this manuscript.
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